Researchers have announced the first drug to make major inroads against liver cancer, one of the more voracious forms of the disease.
Will change practice
Dr Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, added, "This is going to change the standard of practice."
Trial ended early
Patients receiving the drug lived a median of 10.7 months, compared with only 7.9 months for those on a placebo. Time to cancer progression was 5.5 months in the Nexavar group, versus only 2.8 months in the placebo group. The findings were so positive that the study was terminated early.
30% reduced risk of recurrence
When chemotherapy was given both before and after surgery to remove liver metastases in colourectal cancer patients, the risk of the liver tumour recurring was reduced almost 30 percent.